Abdominal Aortic Aneurysm and Liver Fibrosis: Clinical Evidence and Molecular Pathomechanisms DOI Open Access
Mohamad Jamalinia, Amedeo Lonardo, Ralf Weiskirchen

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 3440 - 3440

Published: April 7, 2025

To stimulate further research, this review summarizes studies linking liver fibrosis with the risk of abdominal aortic aneurysms (AAA). AAA is defined as a permanently weakened and dilated aorta, which develops due to inflammation tunica media, activation renin-angiotensin-aldosterone system, immune system activation, coagulation disorders. Typically asymptomatic, often incidentally detected through imaging done for symptoms or part screening programs. follows variable course has mortality rate strongly dependent on age sex. Risk factors include age, male sex, ethnicity, family history AAA, lifestyle habits, arterial hypertension, dyslipidemia, comorbid atherosclerotic cardiovascular disease. Conversely, individuals type 2 diabetes, female certain ethnicities are at reduced AAA. Liver fibrosis, resulting from chronic diseases owing varying etiologies, increasingly recognized potential contributor development. Evidence indicates that metabolic dysfunction-associated steatotic disease (MASLD) other conditions may intensify inflammatory pathways shared thereby potentially exacerbating progression. This specifically examines epidemiology associated link between fibrosis. It also highlights pathomechanisms, including systemic inflammation, oxidative stress, extracellular matrix remodeling, contribute both conditions. Although these findings underscore significant overlaps in profiles, additional research needed clarify whether truly confer protection against if association influenced by confounding variables. Ultimately, addressing open questions will help guide targeted therapeutic interventions identification novel biomarkers predict

Language: Английский

Chronic Obstructive Pulmonary Disease and Type 2 Diabetes Mellitus: Complex Interactions and Clinical Implications DOI Open Access
Lucreția Anghel, Anamaria Ciubară,

Diana Pătraș

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(6), P. 1809 - 1809

Published: March 7, 2025

Chronic obstructive pulmonary disease (COPD) and type 2 diabetes mellitus (T2DM) are highly prevalent chronic conditions, frequently coexisting due to their shared pathophysiological mechanisms risk factors. Epidemiological studies estimate that up 30% of COPD patients have comorbid T2DM, contributing worsened progression, more hospitalizations, higher mortality rates. Systemic inflammation in contributes insulin resistance by increasing pro-inflammatory cytokines (TNF-α, IL-6, CRP), which impair glucose metabolism beta-cell function. Conversely, hyperglycemia T2DM exacerbates oxidative stress, leading endothelial dysfunction, reduced lung function, impaired repair mechanisms. A comprehensive narrative review was conducted evaluate the interplay between examining mechanisms, clinical consequences, management strategies. The co-occurrence accelerates development, elevates hospitalization rates, deteriorates overall prognosis. Pharmacological interactions complicate illness treatment, requiring a multidisciplinary therapy strategy. Recent data underscore need integrate palliative care, facilitate decision-making, provide psychological support enhance patient outcomes. Efficient COPD-T2DM comorbidity necessitates customized, interdisciplinary strategy targets both respiratory metabolic health. Preliminary prognostic dialogues, holistic lifestyle modifications can improve quality life results.

Language: Английский

Citations

1
Abdominal Aortic Aneurysm and Liver Fibrosis: Clinical Evidence and Molecular Pathomechanisms DOI Open Access
Mohamad Jamalinia, Amedeo Lonardo, Ralf Weiskirchen

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 3440 - 3440

Published: April 7, 2025

To stimulate further research, this review summarizes studies linking liver fibrosis with the risk of abdominal aortic aneurysms (AAA). AAA is defined as a permanently weakened and dilated aorta, which develops due to inflammation tunica media, activation renin-angiotensin-aldosterone system, immune system activation, coagulation disorders. Typically asymptomatic, often incidentally detected through imaging done for symptoms or part screening programs. follows variable course has mortality rate strongly dependent on age sex. Risk factors include age, male sex, ethnicity, family history AAA, lifestyle habits, arterial hypertension, dyslipidemia, comorbid atherosclerotic cardiovascular disease. Conversely, individuals type 2 diabetes, female certain ethnicities are at reduced AAA. Liver fibrosis, resulting from chronic diseases owing varying etiologies, increasingly recognized potential contributor development. Evidence indicates that metabolic dysfunction-associated steatotic disease (MASLD) other conditions may intensify inflammatory pathways shared thereby potentially exacerbating progression. This specifically examines epidemiology associated link between fibrosis. It also highlights pathomechanisms, including systemic inflammation, oxidative stress, extracellular matrix remodeling, contribute both conditions. Although these findings underscore significant overlaps in profiles, additional research needed clarify whether truly confer protection against if association influenced by confounding variables. Ultimately, addressing open questions will help guide targeted therapeutic interventions identification novel biomarkers predict

Language: Английский

Citations

0